Janux Therapeutics (NASDAQ:JANX) Coverage Initiated by Analy

Jonestrading assumed coverage on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research report released on Tuesday, Benzinga reports. The firm issued a buy rating and a $70.00 price objective on the stock. Other equities analysts also recently issued research reports about the company. Cantor Fitzgerald assumed coverage on Janux Therapeutics in a […]

Related Keywords

United States , China , America , Immunomodulators Tracir , William Blair , Engagers Tractr , Nisa Investment Advisors , China Universal Asset Management Co , Citigroup Inc , Tower Research Capital , Cantor Fitzgerald , Janux Therapeutics Inc , Barclays Plc , Janux Therapeutics , Free Report , Get Free Report , Investment Advisors , Research Capital , Universal Asset Management , Tumor Activatedt Cell Engagers , Tumor Activated Immunomodulators , Janux Therapeutics Daily , Nasdaq Janx , Janx , Medical , Initiated Coverage , Jonestrading ,